Clinical trial study on the therapeutic effect of Tenofovir besides routine drug regime (standard of care) in patients with Coronavirus disease 2019 (COVID-19)

Comparison of the Effectiveness of Tenofovir antiviral drug beside routine drug regime (standard of care) in COVID-19 patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200422047168N1

Enrollment

Registered

2020-04-29

Start date

2020-04-18

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19. Covid-19, confirmed cases, positive test result

Interventions

Intervention 1: Intervention group: On the first day, patients will receive routine drug regime (standard of care) daily for 7 days. In addition to the above drugs, Alfamed Tenofovir is given to 25 mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1- People over 18 years of age, 2- Real-time PCR positive test result for SARS-CoV-2 virus was positive after sampling (nasopharynx and oropharynx swab samples). 3. The manifestations of pneumonia caused by the virus in CT scans of their lungs are quite obvious. 4- They have 93% or lower O2 Saturation percentage

Exclusion criteria

Exclusion criteria: 1- History of renal failure, 2- Taking drugs that interfere with Tenofovir 3. Patients who have been admitted to other clinical trials

Design outcomes

Primary

Measure	Time frame
Reduce the mortality rate of patients with Covid-19. Timepoint: days 0-7. Method of measurement: Based on the percentage of discharged Covid-19 patients.	—

Secondary

Measure	Time frame
Treatment period. Timepoint: 0-7. Method of measurement: Based on the days numbers of the drug usage.;Duration of infection. Timepoint: 0-7. Method of measurement: Based on the patient's clinical symptoms.;Duration of admission time. Timepoint: 0-7. Method of measurement: Number of admission days due to Covid-19.;Duration of ICU admission time. Timepoint: 0-7. Method of measurement: Number of ICU admission days due to Covid-19.;Fever. Timepoint: 0-7. Method of measurement: Rising body temperature.;Blood oxygen saturation percentage. Timepoint: 0-7. Method of measurement: O2 saturation percentage.;Respiratory rate. Timepoint: 0-7. Method of measurement: respiratory rate per minute.;Heart rate. Timepoint: 0-7. Method of measurement: heart rate per minute.;Discharge situation. Timepoint: 0-7. Method of measurement: Alive or dead.;Use non-invasive respiratory methods. Timepoint: 0-7. Method of measurement: Patients percentage that be supported by non-invasive breathing methods.;Use invasive respiratory methods. Timepoint: 0-7. Method of measurement: Patients percentage that be supported by invasive breathing methods.	—

Measure

Time frame

Treatment period. Timepoint: 0-7. Method of measurement: Based on the days numbers of the drug usage.;Duration of infection. Timepoint: 0-7. Method of measurement: Based on the patient's clinical symptoms.;Duration of admission time. Timepoint: 0-7. Method of measurement: Number of admission days due to Covid-19.;Duration of ICU admission time. Timepoint: 0-7. Method of measurement: Number of ICU admission days due to Covid-19.;Fever. Timepoint: 0-7. Method of measurement: Rising body temperature.;Blood oxygen saturation percentage. Timepoint: 0-7. Method of measurement: O2 saturation percentage.;Respiratory rate. Timepoint: 0-7. Method of measurement: respiratory rate per minute.;Heart rate. Timepoint: 0-7. Method of measurement: heart rate per minute.;Discharge situation. Timepoint: 0-7. Method of measurement: Alive or dead.;Use non-invasive respiratory methods. Timepoint: 0-7. Method of measurement: Patients percentage that be supported by non-invasive breathing methods.;Use invasive respiratory methods. Timepoint: 0-7. Method of measurement: Patients percentage that be supported by invasive breathing methods.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Shokati

Ahvaz University of Medical Sciences

zahrashokati@gmail.com+98 61 3333 5678

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026